

# Bridget Hodkinson

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/172547/publications.pdf>

Version: 2024-02-01

16  
papers

257  
citations

933447

10  
h-index

940533

16  
g-index

17  
all docs

17  
docs citations

17  
times ranked

412  
citing authors

#	ARTICLE	IF	CITATIONS
1	Navigating COVID-19 in the developing world. <i>Clinical Rheumatology</i> , 2020, 39, 2039-2042.	2.2	10
2	Points to consider in cardiovascular disease risk management among patients with rheumatoid arthritis living in South Africa, an unequal middle income country. <i>BMC Rheumatology</i> , 2020, 4, 42.	1.6	10
3	HLA-DRB1 Amino Acid Positions and Residues Associated with Antibody-positive Rheumatoid Arthritis in Black South Africans. <i>Journal of Rheumatology</i> , 2019, 46, 138-144.	2.0	6
4	Comparison of the diagnostic potential of three anti-citrullinated protein antibodies as adjuncts to rheumatoid factor and CCP in a cohort of South African rheumatoid arthritis patients. <i>Rheumatology International</i> , 2018, 38, 993-1001.	3.0	7
5	Diagnostic utility of, and influence of tobacco usage and genetic predisposition on, immunoglobulin A, rheumatoid factor and anti-citrullinated peptide auto-antibodies in South African rheumatoid arthritis patients. <i>African Health Sciences</i> , 2018, 18, 295-303.	0.7	3
6	Combination leflunomide and methotrexate in refractory rheumatoid arthritis: a biologic sparing approach. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2016, 8, 172-179.	2.7	20
7	Pitfalls in the assessment of smoking status detected in a cohort of South African RA patients. <i>Rheumatology International</i> , 2016, 36, 1365-1369.	3.0	5
8	Biologic therapy for rheumatoid arthritis in developing countries—a place for non-TNF inhibitors as first-line treatment?. <i>Rheumatology</i> , 2015, 54, 208-209.	1.9	11
9	Circulating anti-citrullinated peptide antibodies, cytokines and genotype as biomarkers of response to disease-modifying antirheumatic drug therapy in early rheumatoid arthritis. <i>BMC Musculoskeletal Disorders</i> , 2015, 16, 130.	1.9	27
10	Tight control of rheumatoid arthritis in a resource-constrained setting: a randomized controlled study comparing the clinical disease activity index and simplified disease activity index. <i>Rheumatology</i> , 2015, 54, 1033-1038.	1.9	10
11	ImmunoChip Identifies Novel, and Replicates Known, Genetic Risk Loci for Rheumatoid Arthritis in Black South Africans. <i>Molecular Medicine</i> , 2014, 20, 341-349.	4.4	21
12	Rheumatoid arthritis in the developing world: stepping up to the challenge. <i>Clinical Rheumatology</i> , 2014, 33, 1195-1196.	2.2	13
13	South African recommendations for the management of rheumatoid arthritis: An algorithm for the standard of care in 2013. <i>South African Medical Journal</i> , 2013, 103, 576.	0.6	34
14	HLA-DRB1 shared epitope genotyping using the revised classification and its association with circulating autoantibodies, acute phase reactants, cytokines and clinical indices of disease activity in a cohort of South African rheumatoid arthritis patients. <i>Arthritis Research and Therapy</i> , 2011, 13, R160.	3.5	20
15	The diagnostic utility of the anti-CCP antibody test is no better than rheumatoid factor in South Africans with early rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2010, 29, 615-618.	2.2	16
16	Circulating Cytokine Profiles and Their Relationships with Autoantibodies, Acute Phase Reactants, and Disease Activity in Patients with Rheumatoid Arthritis. <i>Mediators of Inflammation</i> , 2010, 2010, 1-10.	3.0	41